Metraipolis › archive › dc_4a8544aa910d

Clinical and cost benefit of rapid molecular screening for carbapenem-resistant organisms: a seven-year analysis in a tertiary hospital — Europe PMC PMID:42108490

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42108490
DOI
10.1186/s13756-[numero omesso]-7
License (as archived)
solo-consultazione
Archived
2026-10-08T09:10:14.563Z
SHA-256 of the archived text
38346cba3b300cbb13456d4cccc00ded5f6ac5e3f7a787df9c80a976f2ec49fb
Stable URL of this page
https://metraipolis.com/documento/dc_4a8544aa910d

How to cite

Clinical and cost benefit of rapid molecular screening for carbapenem-resistant organisms: a seven-year analysis in a tertiary hospital — Europe PMC PMID:42108490 — Europe PMC (en), https://europepmc.org/article/MED/42108490 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4a8544aa910d (Metraipolis archive dc_4a8544aa910d, sha256 38346cba3b300cbb13456d4cccc00ded5f6ac5e3f7a787df9c80a976f2ec49fb)
BibTeX
@misc{dc4a8544aa910d,
  title = {Clinical and cost benefit of rapid molecular screening for carbapenem-resistant organisms: a seven-year analysis in a tertiary hospital — Europe PMC PMID:42108490},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42108490},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4a8544aa910d; sha256 38346cba3b300cbb13456d4cccc00ded5f6ac5e3f7a787df9c80a976f2ec49fb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42108490. Agents can read the archived copy with the MCP tool read_document.